Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brazil Blazing Trail on Excipient GMPs

This article was originally published in PharmAsia News

Executive Summary

Brazil’s ANVISA shows global leadership in regulating pharmaceutical excipients with proposed excipient GMPs. Comments were generally favorable, though there were concerns about the extent of applicability to foreign excipient makers.

You may also be interested in...



ICH Enhances Regulators’ Roles While Preserving Industry Access

The International Conference on Harmonization strengthens the hand of regulatory authorities in consensus-based discussions with industry, while applauding the growing role of non-ICH authorities in its expert working groups.

Proper Venue Sought for Resolving Global Pharma Supply Chain Crisis

Who can coordinate a global response to the pharma supply chain crisis? Industry and regulators debate whether ICH, which smoothed over GMP differences among developed nations, is the right institution for today’s problems, which emanate from non-ICH countries. FDA’s Woodcock describes what the goal should be. IPEC proposes forum to help launch global excipient GMPs. Time is short, with excipient GMPs proliferating in China, Brazil, elsewhere. Support grows for approaching ICH to establish a Q7B guideline for excipients comparable to the Q7A guideline for active ingredients. Big impact expected from Rep. John Dingell’s FDA Globalization Act based on latest discussion draft. Second round of GMP revisions may call for supplier audits, FDA says. IPEC completes excipient qualification guidelines, which set forth process for negotiating quality agreements. The EU advances anti-counterfeiting, regulatory cooperation efforts. Third-party supplier auditing poised for growth.

Why US FDA Requested Ranitidine Withdrawal, And How Other Drugs Could Follow

FDA made request after finding unacceptable levels of nitrosamine NDMA can form during storage above room temperature or beyond expiry. Forthcoming guidance on detecting impurities like nitrosamines in any drug will call for routine testing as well as a chemical risk assessment “to look at what is the probability of generating them.

Topics

UsernamePublicRestriction

Register

SC082319

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel